+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
8 Apr 2020

Gilead Sciences, Second Genome ink collaboration strategic deal in biomarker and inflammatory bowel disease drug discovery

Gilead Sciences, Inc and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD).

Under the terms of the agreement, Second Genome will utilize its proprietary microbiome analytics platform to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines. This work will harness the latest insights in microbiome science to help inform patient stratification and optimize potential treatments for patients in the future. The platform, in combination with additional discovery and development tools, will also seek to identify new targets and drug candidates relevant to IBD. This will include the identification of up to five novel IBD targets or drug candidates over the next four years, with an option to extend the collaboration for an additional two years.

Second Genome will receive US $38 million in an upfront payment, and up to approximately US $300 million in success-based preclinical, clinical, regulatory and commercial milestones for each of five target discovery programs as well as low double-digit royalties for any approved products. In addition, it will receive success-based milestones for each validated biomarker delivered under the agreement.

Gilead will have the option to worldwide rights for up to five programs for all diseases as well as exclusive rights to all biomarkers developed under the collaboration.

KPE-C-08 KPE’s Advance Diploma in Pharmaceutical Strategic Business Management

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.